The completion of the human genome project has revealed that humans have about 30000 genes, and more than half of them encode unknown proteins. They include a number of proteins that are thought to be integrally related to pathological disorders and other biological phenomena. Thus, they are anticipated to be potentially useful as protein drugs and/or as targets for drug innovation and development. In the postgenome era, the focus of life science research has shifted to the functional and structural analysis of proteins, such as disease proteomics and structural genomics. Proteomics comprises the comprehensive analysis of all proteins with regard to their temporal and special, or qualitative and quantitative aspects. Structural genomics provides information about the relationship between protein function and 3D-structure. Thus, many scientists expect that these approaches will offer tremendous potential for discovery of novel drug targets and unique lead compounds for drug development.
prises the comprehensive analysis of all proteins with regard to their temporal and special, or qualitative and quantitative aspects. Structural genomics provides information about the relationship between protein function and 3D-structure. Thus, many scientists expect that these approaches will offer tremendous potential for discovery of novel drug targets and unique lead compounds for drug development.
In recent years, cytokine or antibody therapy has also received attention for advanced drug therapies in the twentyfirst century, and attempts are being made to develop a wide variety of therapeutic proteins for diseases including cancer, hepatitis, and rheumatism. [1] [2] [3] [4] [5] [6] [7] [8] [9] For this reason, pharmacoproteomic based drug development for protein therapies has received even greater attention as a future technology for the creation of therapeutic proteins.
It is a well-known fact that the later half of the 20th century brought about the identification of a number of bioactive proteins, anticipated as "dream" protein drugs for refractory diseases. However, as many cases in the past demonstrate, these proteins are limited in their clinical application because of unexpectedly low therapeutic effects. 5, 6, [10] [11] [12] The reason for this limitation is that these proteins are immediately degradated by various proteases in vivo and rapidly excreted from blood circulation. Therefore, frequent administration at an excessively high dose is required to obtain their therapeutic effects in vivo, which causes disturbance of homeostasis and unexpected side effects. Additionally, cytokines generally show pleiotropic actions through a number of receptors in vivo, making it difficult to elicit the desired effect without simultaneously triggering side effects as well. From this standpoint, creation of novel technologies that overcome the problems peculiar to bioactive proteins is absolutely essential for advancement of pharmaco-proteomic based drug development for protein therapies. These technologies are suitable for Drug Delivery Systems (DDS) that seek to maximize the therapeutic potency using proteins. It can thus be called a crossover, bridging the gap between basic research in the post-genome era and 21st century drug therapies.
Thus, our group's research has the following three goals (details of which will be taken up in separate sections to follow): 1) development of a powerful system that rapidly allows creation of functional muteins with a higher receptor affinity and receptor specificity based on the phage display technique, 13) 2) establishment of a novel polymer-conjugation system that can improve the stability of proteins in vivo and selectively increase their therapeutic effects, 13, 14) 3) design of functional polymeric carriers (modifiers) with DDS capabilities such as targeting and controlled release. 15) We are now attempting to fuse [1] [2] [3] to create a protein-drug innovation system as the basis of DDS technology to further promote the pharmaco-proteomic based drug development for protein therapies. In this review, we will describe this protein-drug innovation system in as much detail as space permits.
CREATING A SYSTEM FOR PRODUCING ARTIFICIAL FUNCTIONAL MUTEINS WITH ADVANCED MEDICI-NAL APPLICATIONS
Seeking therapeutic applications of bioactive proteins, many research institutes for biotechnology have experimented in the past with the creation of muteins that had selectivity and high affinity for specific receptors by substituting amino acids with site-directed mutagenesis, as typified by the Kunkel method. [16] [17] [18] [19] [20] [21] [22] However, the creation of muteins by such point mutation approaches requires simulation of the mutant's 3D-structure and generation of individual mutants by replacement of the bioactive protein amino acids individually through a trial and error process. Additionally, each mutein's functional capabilities must be assessed individually to see if it achieves the desired goal. For these reasons, traditional approaches not only required a great investment of time and effort to create desired muteins, but also put limitations on the variety of mutational types that could be produced, making it difficult to achieve results as expected.
In recent years, the phage display system has been developed for the rapid and exhaustive determination of high affinity ligands for given targets (i.e., a target molecule, particle and/or cell) by utilizing information on it's life cycle.
23) The advantages of a phage display system are 1) easily preparing a library consisting of structural variants of a polypeptide as diverse as over one hundred million and 2) isolating several molecules binding to a targeted ligand from this library in a few weeks. Thus, phage libraries displaying polypeptides have extensively been applied to identification of specific molecules with high affinity for targeted ligands. The phage display method is thus expanding its range of applications as a standard technology for quickly and thoroughly screening out bond molecules. [24] [25] [26] [27] [28] However, at present it appears to only be utilized as a way of identifying antibodies and peptides with high affinity for specific targets. There appear to have been no cases of exposing bioactive proteins like cytokines on phage surfaces.
Given the background outlined above, we first used the phage display system to quickly and efficiently create functional muteins with advanced medical value. Functional muteins with improved affinity and specificity for target receptors were selected from more than 10 8 types of structural mutant proteins displayed on phage particles. This is a neoDarwinist molecular evolution strategy for pharmaco-proteomic based drug development for protein therapies. An example in previous structure-activity relationship research using site-directed mutagenesis like the alanine scan is that lysine residues (including Lys11, Lys65/Lys90) were generally thought to be indispensable in the formation of TNF-a (Tumor Necrosis Factor-a) 3D-structures (i.e., trimeric structures) and receptor bonding. Because lysine residues have critical roles in protein structure or ligand-receptor binding, the replacement of lysine residues with amino acids other than basic ones such as arginine was assumed to be impossible without loss of bioactivity in point mutation analysis without being limited to TNF-a. In fact, no such muteins existed with which all lysine residues were substituted for other amino residues with full bioactivity (i.e., a lysine-deficient mutant) until recently. However, we succeeded in creating lysine-deficient mutant TNF-as that retained its original bioactivity, with some of them displaying 13 times the bioactivity within an in vivo therapeutic window of wild-type TNF-a (wTNF-a) Fig. 1 . Our results have shaken the fixed concept mentioned before. Analysis using BIAcore and ultracentrifugation suggested that lysine-deficient mutant TNF-as have affinities for TNF-R1 and TNF-R2 equivalent to that of wildtype TNF-a. We also confirmed through ultracentrifugation and gel filtration chromatography that they formed trimeric structures. These results lead us to believe that we have, through affinity selection using TNF-R1 and anti-TNF neutralizing antibody, successfully isolated lysine-deficient mutant TNF-as with full bioactivity and correct tertiary structure from the phage library consisting of 10 8 variant TNF-a with replacement of all lysine residues with other residues. Using these technologies, we have already created a number of functional TNF-a muteins and improved their affinity and in vivo stability. We also constructed lysine-deficient libraries of other cytokines, receptor proteins, and antibodies to create lysine-deficient muteins with full activity. Our system for applying the phage surface method to the construction of artificial functional muteins has not only shown the tremendous power for the DDS-based pharmaco-proteomic based drug discovery and development for protein therapy technology, but also redefined the concepts of protein engineering and the correlation between protein structure and activity, findings that have not been previously obtained by mutational technologies like the alanine scan. Remarkable progress in proteomics and structural genomics will accelerate the implementation of pharmaco-proteomic based drug development for protein therapies through combination with our neo-Darwinist molecular evolution strategy in the near future.
At the same time, progress in bioinformatics has provided a greater understanding of the relationship between amino acid sequences and structures of proteins and their functions, which will allow the prediction of structures and functions of unknown proteins, given an amino acid sequence. Thus, this will enable us to design amino acid sequences with a desired function and structure and efficiently simulate organic substances that mimic their forms and functions. To improve bioinformatics, structural muteins having a vast amount of diversity with regard to a wide variety of proteins must be created, and information on their functional properties such as ligand-receptor binding and bioactivity must be accumulated to determine the structure-activity relationship. Our group's "system of creating functional muteins" was capable of creating a library of more than 10 8 structural mutants in a single week, making it an important technology for the gathering of such information. In addition to the functional assessment of artificial functional TNF-a and other proteins, as described above, we are currently working on X-ray crystallography as well, in hopes that the combination of these two forms of technology will contribute to new developments in bioinformatics in the near future.
A NEW METHOD FOR SITE-SPECIFIC POLYMER-CONJUGATION
Following the 1980's, attachment of water-soluble polymers like PEG (polyethylene glycol) to the surface of bioactive proteins (polymer-conjugation) has been devised in the field of protein drug development including DDS to overcome problems in their clinical application. [29] [30] [31] [32] [33] [34] [35] [36] Covalent conjugation of proteins with PEG is specifically referred to as PEGylation. Polymer-conjugation of bioactive proteins decreases their renal excretion rate due to the increased molecular size. In addition, since the water-soluble polymers cover the protein surface, the attack from proteases is blocked by steric hindrance, resulting in prolongation of the in vivo halflife Fig. 2 . By a similar effect of steric hindrance, antigenecity and immunogenicity in immune response decrease, resulting in prolongation of in vivo clearance and stabilization. All of these advantages lead to an increase in internal stability, in turn making it possible to decrease both administration doses and times. Polymer-conjugation has been recognized as one of the most efficient ways of improving therapeutic potency of proteins among several DDS technologies for pharmaco-proteomic based drug development for protein therapies. However, bioconjugated proteins described to date have mostly been limited to enzymes such as Adenosine Deaminase and Superoxide Dismutase (SOD) acting on lowmolecular-weight materials. [37] [38] [39] In our previous study, the specific activity of bioconjugated SOD was not associated with the molecular weight of PEG and was determined only by the modification rate of active sites Fig. 3 . These results suggest that SOD-substrate complex formation was possible without steric hindrance by water-soluble polymeric modifiers attached to SOD because of the low molecular weight of the substrate (superoxide anion). On the other hand, IL-6 (Interleukin-6), 40) which requires binding to high molecular receptors for the development of activity, displayed decreases in specific activity with an increase in the modification rate by water-soluble macromolecules, and the degree of this decrease was more notable when the molecular weight of the modifying macromolecule was larger Fig. 3 . For this reason, in bioactive proteins consideration should be given to severe loss of activity derived from inhibition of binding to receptor molecules caused by steric hindrance formed in the polymeric modifier, in addition to a decrease in the specific activity due to modification of the active sites. Therefore, polymer-conjugation of bioactive proteins like cytokines that need binding with macromolecular receptors is advantageous in that it blocks the attacks of proteases by steric hindrance more effectively when the molecular weight of the modifying is larger but is overwhelmingly disadvantageous in that it also inhibits receptor binding, causing a reduction in the specific activity. Furthermore, the increase in the molecular weight by water-soluble polymeric modifiers improves the retention of the proteins in the circulation as a result of a decrease in the renal excretion rate, but this simultaneously causes marked restriction of their transport from the circulation to tissue. Thus, polymer-conjugation of physiologically active proteins that need binding with macromolecular receptors to produce their activity do good as well as harm.
With these problems described above in mind, we attempted to improve the polymer-conjugation system using TNF-a and IL-6 as model proteins (therapeutic effect: antitumor effect for TNF-a, thrombopoietic effect for IL-6). [13] [14] [15] [40] [41] [42] [43] [44] In summary, a loss in bioactivity could not be avoided but we: 1) selected the optimal modifying molecule according to the purpose of polymer-conjugation and properties of individual physiologically active proteins and 2) accumulated basic data such as the molecular weight-modification rate-activity relationship in detail and then determined the optimal polymer-conjugation conditions to a) increase plasma half-life and stability, b) control behavior in the body (well-balanced tissue transport), and c) selectively enhance desirable therapeutic activities of bioactive proteins without increasing their side effects. This c) selective enhancement of therapeutic effects in bioactive proteins was mainly brought about by a decrease in given dosages with increased in vivo stability and by prevention of transport to tissues that were affected by the side effects. For example, we succeeded in increasing the anti-tumor effect of TNF-a and the thrombopoietic effect of IL-6 by 100 fold and 500 fold, respectively, without any side effects Fig. 4 . From this standpoint, polymer-conjugation of bioactive proteins that requires binding to high molecular receptors for the development of activity has been attempted globally, and PEGylated Interferon-a has been used in clinical treatment of hepatitis C. 31, 33, 35) However, this approach is limited by the frequent substantial loss of protein specific activity associated with polymer-conjugation. Lysine amino groups of proteins are often used as substrates for polymer-conjugation because they are highly reactive and the bionconjugation reaction is mild enough to minimize disruption of the protein structure. This polymer-conjugation, however, is nonspecific and occurs at the N terminus as well as all internal lysine residues, some of which may be in or near protein active sites. Such bioconjugated proteins thus consist of positional isomers with polymeric modifiers at various sites that have distinct activities and other characteristics. Such bioconjugated isomer mixtures can therefore have inconsistent therapeutic effects. To overcome this problem, site-specific polymer-conjugation can be achieved through a free thiol in the engineered proteins. 14, 45) This efficacy of this approach is compromised, however, by an extremely low yield of bioconjugated proteins and a substantial loss of activity owing to the introduction of a free thiol residue.
Based on these points, we successfully developed a novel polymer-conjugation system fused to a "neo-Darwinist model of molecular evolution." In other words, we first applied the phage display system to create fully bioactive lysine-deficient mutant proteins and then carried out site-specific polymer-conjugation to improve therapeutic potency. Regarding this site-specific polymer-conjugation, the maximal yield of bioconjugated protein was Ͼ90% with superior molecular uniformity because the N terminus of the protein is specifically bioconjugated.
An example in TNF-a is where amino groups of all six internal lysine residues are also targets for polymer-conjugation, and studies using site-directed mutagenesis analysis have reported that Lys11 and Lys90 are essential for the protein's homotrimer formation as an active form and for interaction with its receptor, respectively. [46] [47] [48] Therefore, traditional polymer-conjugation as mentioned has caused a substantial loss of specific activity. Indeed, this is supported by our results, in which randomly mono-PEGylated wild-type TNF-a (ran-PEG-TNF-a) was heterogeneous at the molecular level and had Ͻ10% of the specific bioactivity of unmodified wild-type TNF-a.
On the other hand, the N terminus of TNF-a is not indispensable for function because a deletion mutant of TNF-a lacking eight residues at the N terminus retains full bioactivity. In such instances, site-specific mono-PEGylated TNF-a (sp-PEG-TNF-a) was uniform at the molecular level and had similar bioactivity (80%) to that of unmodified mTNF-a. Additionally, this sp-PEG-TNF-as displayed greater antitumor therapeutic potency than ran-PEG-TNF-a because of an increase in plasma half-life. Thus, we are now attempting to study the clinical application of sp-PEG-TNF-as. On the other hand, we are currently trying to construct lysine-deficient forms of IFN-a, TNF-R1, antibody specific to TNF-a (scFv), and IL-6 with full activity and site-specific PEGylation of their N termini.
DESIGNING OF FUNCTIONAL POLYMERIC CARRIERS WITH DDS CAPABILITIES
The fate and distribution of conjugates between polymeric carriers and drugs is determined by their physicochemical properties, such as electric charge and hydrophilic balance. Therefore, we have been trying to design polymeric carriers with useful functions such as targeting and controlled release capability, which can closely regulate their behavioral characteristics in vivo, to achieve optimization of drug therapy by polymer conjugation.
For example, we have previously reported that PEG and PVP are useful and powerful polymeric carriers for improvement of the plasma half-lives of proteins. Furthermore, the copolymer of divinyl ether and maleic anhydride (DIVEMA) has antitumor activity (induction of INF-g and activation of immunocompetent cells) 44) and the PVP introduced lauric acid selectively accumulated in the spleen. 43) These novel polymeric modifiers will be used to increase plasma halflives of conjugated bioactive proteins and to provide useful DDS functions for control of the behavior of proteins in vivo, which cause further increase their therapeutic activity and safety by isolation of desirable activity for clinical use.
From a series of research, we have synthesized a novel polymeric drug carrier, polyvinylpyrrolidone-co-dimethyl maleic anhydride (PVD), which accumulated in the kidney and displayed controlled-release in response to changes in pH. 15) PVD binds to an amino group of a protein by forming an amide bond through its acid anhydride group at a pH of over 8.0 and then reversibly dissociates from the amino group, changing in pH to a slightly acidic form. In inflammatory tissue and tumor tissue, the pH is lower than normal. Therefore, if PVD is used in nephritis and renal cancer, PVD is expected to accumulate in the kidneys and gradually release the drugs. We found that about 80% of the dose of PVD selectively accumulated in the kidneys 24 h after intravenous injection, and about 40% remained 96 h after beginning the treatment Fig 5. PVD was selectively taken up by renal proximal tubular epithelial cells and no cytotoxicity was noted. Higher doses did not produce toxicity in the kidneys or other tissues. Additionally, PVD-modified superoxide dismutase accumulated in the kidneys after intravenous ad- Foreshadowing the aging of society, renal disease is a serious problem that will increase worldwide. 49) Dialysis and renal translation are two treatment options. Although they are life-saving, they are expensive and do not restore normal health. Therefore, new strategies must be developed to treat patients with chronic kidney disease. From this standpoint, we are attempting to construct a new strategy for these patients by fusing the two systems mentioned, the mutein-creation system using a phage display technique and the sitespecific polymer-conjugation system.
CONCLUSION
In this review, we presented the protein-drug innovation system as the basis of DDS technology in three approaches. We believe that our system will play a critical role in pharmaco-proteomic based drug development for protein therapies as translational research. Recently, gene shuffling [50] [51] [52] and artificial gene encoding systems 53) have received a great deal of attention. These approaches can create artificial proteins constructed with amino acids or sequences that do not exist in nature, though they have unfortunately not been able to produce bioactive proteins that can be applied to clinical settings. These technologies can be adapted to our systems for the screening, creation, stabilization, or functioning of non-natural proteins. We are now trying to construct a new strategy for production of artificial proteins by applying gene shuffling to the phage display system.
Making progress in pharmaco-proteomic based drug discovery and development for protein therapie requires the production of a wide variety of proteins and protein structural mutant types, development of a high-throughput screening of their function (i.e., on the status and strength of ligand-receptor bonds), and thorough evaluation of the relationship between these factors and a protein's structure. Additionally, pharmaco-proteomic based drug discovery and development for protein therapie will not be achieved until bioinformatics allow the prediction of the functions and structures of unknown proteins using genome sequencing information. Our strategy, as outlined above, may become an essential basic technology for large-scale and high-throughput analysis of protein functions.
We are confident that our research has taken a number of important steps towards understanding the relationship between a protein's function (i.e., medicinal value) and its structure. And we sincerely hope that the results of our research will contribute to the building of a pharmaco-bioinfomatics database that can be used to effectively set parameters for functional artificial proteins in the future. 
